New Heart-Kidney combo drug tested in tiny study
NCT ID NCT06639087
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested a new drug called AZD5462 added to the standard medicine dapagliflozin in people with heart failure and moderate kidney disease. Only 8 participants were enrolled before the study was stopped. The goal was to see if the combination is safe and affects how the body handles salt and kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD5462
- What this could lead to
- If it works, this could point toward a new combination treatment to help people with both heart failure and kidney disease.
- What could go wrong
- This is a very early, tiny study (only 8 people) that was terminated, so results are limited. It may not lead to any new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 3 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Sofia, 1612, Bulgaria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?